Development of a Risk Score and Nomogram to Predict Individual Benefit Attained from the Addition of Adjuvant Chemotherapy in the Treatment of Stage II Colon Cancer

Daniel W. Nelson,Clay Merritt,Shu-Ching Chang,Gary Grunkemeier,Scott R. Steele,Melanie Goldfarb
DOI: https://doi.org/10.1007/s11605-020-04757-6
2020-08-03
Journal of Gastrointestinal Surgery
Abstract:Current guidelines recommend considering adjuvant chemotherapy (AC) for stage II colon cancer (CC) with poor prognostic clinicopathologic and molecular features. However, the relative impact of individual or constellations of high-risk features remains undefined. We developed an individualized point-of-care tool to predict survival benefit attained from the addition of AC.
gastroenterology & hepatology,surgery
What problem does this paper attempt to address?